Skip to main content
Home
Loading...
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube

Menu top

  • Assistance

User account menu

  • Log in
Home

Main navigation

  • Home
  • Programme
Menu Login
Close

Main navigation mobile

  • Home
  • Programme

Menu top

  • Assistance
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
Filters
Filters Close
Poster topics
Poster available until
  • Monday 29 June 2026 (5)
  • Until platform closure (7)
Poster categories
  • Thematic Poster Session (22)
keywords
Session Reference
  • L-TPS01 (12)
  • L-TPS02 (14)
  • L-TPS03 (10)
  • L-TPS04 (13)
  • L-TPS05 (10)
  • L-TPS06 (8)
  • L-TPS07 (14)
  • L-TPS08 (9)
  • L-TPS09 (13)
  • L-TPS10 (14)
  • L-TPS11 (15)
  • x L-TPS12 (11)
  • L-TPS13 (12)
  • L-TPS14 (14)
  • L-TPS15 (12)
  • L-TPS16 (9)
  • L-TPS17 (13)
  • L-TPS18 (13)
  • L-TPS19 (9)
  • L-TPS20 (14)
  • L-TPS21 (8)
  • L-TPS22 (10)
  • L-TPS23 (14)
  • L-TPS24 (14)
  • L-TPS25 (5)
  • TPS01 (14)
  • TPS02 (12)
  • TPS03 (10)
  • TPS04 (12)
  • TPS05 (13)
  • TPS06 (14)
  • TPS07 (9)
  • TPS08 (15)
  • TPS09 (14)
  • TPS10 (11)
  • TPS11 (13)
  • TPS12 (12)
  • TPS13 (11)
  • TPS14 (12)
  • TPS15 (9)
  • TPS16 (12)
  • TPS17 (12)
  • TPS18 (11)
  • TPS19 (11)
  • TPS20 (13)
  • TPS21 (14)
  • TPS22 (11)
  • x TPS23 (11)
  • TPS24 (12)
  • TPS25 (8)
  • TPS26 (16)
  • TPS27 (13)
  • TPS28 (5)
  • TPS29 (6)
  • TPS30 (12)
  • TPS31 (10)
  • TPS32 (12)
  • TPS33 (14)
  • TPS34 (15)
  • TPS35 (11)
  • TPS36 (11)
  • TPS37 (12)
  • TPS38 (12)
  • TPS39 (13)
  • TPS40 (10)
  • TPS41 (14)
  • TPS42 (15)
  • TPS43 (15)
  • TPS44 (14)
  • TPS45 (12)
  • TPS46 (11)
  • TPS47 (14)
  • TPS48 (11)
  • TPS49 (12)
  • TPS50 (9)
  • TPS51 (8)
  • TPS52 (14)
  • TPS53 (12)
  • TPS54 (11)
  • TPS55 (13)
  • TPS56 (13)
  • TPS57 (5)
  • TPS58 (4)
  • TPS59 (12)
  • TPS60 (12)
  • TPS61 (12)
  • TPS62 (13)
  • TPS63 (12)
  • TPS64 (15)
  • TPS65 (14)
  • TPS66 (13)
  • TPS67 (13)
  • TPS68 (11)
  • TPS69 (15)
  • TPS70 (13)
  • TPS71 (9)
  • TPS72 (13)
  • TPS73 (12)
  • TPS74 (10)
  • TPS75 (13)
  • TPS76 (10)
  • TPS77 (7)
  • TPS78 (14)
  • TPS79 (13)
  • TPS80 (11)
  • TPS81 (6)
  • TPS82 (12)
  • TPS83 (6)
  • TPS84 (11)
  • TPS85 (11)
  • TPS86 (13)
  • TPS87 (10)
  • TPS88 (9)
  • TPS89 (7)
  • TPS90 (5)
  • TPS91 (5)
22 results
Thumbnail

D2.271 - The effect of Organic Light Emiting Diode(OLED) phototherapy in atopic mouse model

Thumbnail

D2.274 - Late-onset toxic epidermal necrolysis (TEN) associated with nivolumab: attention to possible cofactors

Thumbnail

D2.261 - Mental health and quality of life in patients with chronic spontaneous urticaria

Thumbnail

D2.265 - Standard dosage vs. increased dosage of non-sedating antihistamines in pharmacotherapy of chronic spontaneous urticaria

Thumbnail

D2.266 - Comparative Efficacy of Dupilumab, Janus Kinase Inhibitors, and Conventional Immunosuppressants on Neuropsychiatric Outcomes in Patients with Atopic Dermatitis: A Retrospective Cohort Study

Thumbnail

D2.267 - Real-World Clinical Outcomes of Chronic Urticaria Patients in Greece: Longitudinal Data from the CURE Registry

Thumbnail

D2.268 - Clinical characteristics and Therapeutic Management of Hereditary Angioedema due to C1-Inhibitor Deficiency: A Retrospective Cohort Study in Colombia

Thumbnail

D2.269 - Predictors of Poor Disease Control in Greek Patients with Chronic Urticaria: Real-World Evidence from the CURE Registry

Thumbnail

D2.270 - Clinical and Laboratory predictors of treatment response among adult Egyptian patients with Chronic Spontaneous Urticaria

Thumbnail

D2.272 - Long-Term Remission Patterns in Chronic Spontaneous Urticaria: A Real-Life Cohort Study

Thumbnail

D2.273 - The frequency of metal sensitisation in patients who are about to undergo joint replacement

Thumbnail

D1.437 - A Decade of Research on Janus Kinase Inhibitors in Atopic Dermatitis: A Global Bibliometric Analysis (2015–2024)

Thumbnail

D1.438 - Dupilumab for Moderate-to-Severe Atopic Dermatitis in Children and Adolescents: Real-Life Assessment of Efficacy and Safety

Thumbnail

D1.442 - Design and Preclinical Development of a Bispecific Antibody Targeting IL11 and TL1A

Thumbnail

D1.443 - Preclinical Development of a Dual LIGHT/TL1A Bispecific Antibody

Thumbnail

D1.446 - Lebrikizumab in patients with urticarial vasculitis - a case series

Thumbnail

D1.447 - Comparison of Disease Duration, Remission, and Other Disease-Related Parameters with the Duration of Omalizumab Treatment in Patients with Chronic Spontaneous Urticaria

Thumbnail

D1.448 - Long-Term Efficacy and Stability of Lebrikizumab in Treating Face/Head and Neck Involvement in Patients with Moderate-to-Severe Atopic Dermatitis

Thumbnail

D1.449 - A Phase 2, Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Briquilimab in Adults with Chronic Urticaria (Trial in Progress)

Thumbnail

D1.439 - Urticaria Voices: Physician-reported perspectives of chronic urticaria care and its treatment in China (UV in China)

Pagination

  • Current page 1
  • Page 2
  • Next page Next
  • Last page Last
Download the app
The congress at your fingertips

Available on

App Store Google Play
QR Code Download
Mobile App Schedule page
Mobile App Home page
Menu social network
  • LinkedIn
  • Facebook
  • X
  • Youtube
© 2026 EAACI
Made with   by CYIM